Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG006 in Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
NCT06440057Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Aug 2024
- Primary completion
- May 2026
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of alveltamig in neuroendocrine carcinoma (NEC), small cell lung cancer (SCLC), sponsored by Zelgen. Started Aug 2024; status: recruiting.
02
Drugs
alveltamig
03
Conditions
neuroendocrine carcinoma (NEC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06440057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440057.